The latest
Mayo Clinic Laboratories’ guidance for subtyping influenza A in response to a CDC advisory for hospitalized patients
William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, joins “Answers From the Lab” for his weekly leadership update with host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Morice shares his biggest takeaways from this year’s J.P. Morgan Healthcare Conference in San Francisco, California, and gives an update on the COVID-19 public health emergency.
Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic, joins host Bobbi Pritt, M.D., on this week’s episode of the "Answers From the Lab" podcast. In this episode, they discuss the ongoing respiratory virus season, a new test for measles available at Mayo Clinic Laboratories, and some tips to stay healthy.
New research by Robin Patel, M.D. and others at Mayo Clinic has found that the use of a “transcriptomic-based cellular deconvolution tool” called CIBERSORTx could help improve the detection of infectious and non-infectious causes of failed joint replacement surgeries.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the latest monkeypox developments, potential scenarios for monkeypox moving forward, and where the VALID Act stands.
In this month's "Hot Topic," Robin Patel, M.D., discusses how the use of multiplex tests may reduce the turnaround time for identifying the cause of bloodstream infections, and how this might impact antibiotic stewardship and patient outcomes.
The field of clinical microbiology has a long and distinguished history at Mayo Clinic. Since the early 1900s, the clinical microbiology team has played important and leading roles in advancing testing and patient care.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update with Bobbi Pritt, M.D. In this episode, Dr. Morice and Dr. Pritt discuss the range of emerging viruses and their variants that are currently in the news.
Matthew Binnicker, Ph.D., director of Mayo Clinic’s Clinical Virology Laboratory, joins the "Answers From the Lab" podcast for a discussion with Bobbi Pritt, M.D. about recent outbreaks of viral infections. In this episode, Dr. Binnicker and Dr. Pritt look at the hepatitis cases in children possibly linked to adenovirus as well as the spread of Monkeypox.
Elitza Theel, Ph.D., director of the Infectious Diseases Serology Lab at Mayo Clinic, joins the "Answers From the Lab" podcast for a discussion with Bobbi Pritt, M.D. about tick-borne disease testing. In this episode, Dr. Theel and Dr. Pritt look at emerging tick-borne illnesses, the tests available to detect these infections, and how to prevent them.
Recognizing Dr. Pritt’s innovative work in medical education, the Infectious Diseases Society of America is highlighting her role as an educator in its monthly series.
Audrey Schuetz, M.D., provides a detailed overview of Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing. Used to screen for the presence of multi-drug resistant gram-negative bacteria in donor stool intended for fecal microbiota transplantation, the screening test is performed on stool or swab samples taken from around the anus to detect potentially harmful ESBL bacteria that could jeopardize the outcomes of fecal microbiota transplants -- especially in patients who carry the bacteria in their gut without getting sick.
Joseph Yao, M.D., explains how Mayo Clinic Laboratories’ SARS four-target test for viral respiratory disease can enhance patient care. The test detects RNA from SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus, or RSV. RSV — which poses significant risks for infants and patients with underlying health conditions — can be treated if diagnosed early.